Intensity Therapeutics

Westport, United States Founded: 2012 • Age: 14 yrs
Oncology drugs are reformulated for late-stage solid tumors.

About Intensity Therapeutics

Intensity Therapeutics is a company based in Westport (United States) founded in 2012. It operates as a HealthTech. Intensity Therapeutics has raised $20.98 million across 6 funding rounds from investors including Fastforward Innovations, SalvaRx and VCapital. The company has 16 employees as of December 31, 2024. Intensity Therapeutics offers products and services including INT230-6 and DfuseRx℠.

  • Headquarter Westport, United States
  • Employees 16 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Intensity Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0
    0
    as on Dec 31, 2024
  • Net Profit
    $-16.27 M
    -54.37
    as on Dec 31, 2024
  • EBITDA
    $-16.56 M
    -102.64
    as on Dec 31, 2024
  • Total Equity Funding
    $20.98 M (USD)

    in 6 rounds

  • Latest Funding Round
    $6.5 M (USD), Series B

    Nov 02, 2018

  • Investors
  • Employee Count
    16

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Intensity Therapeutics

Intensity Therapeutics is a publicly listed company on the NASDAQ with ticker symbol INTS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: INTS . Sector: Health technology · USA

Products & Services of Intensity Therapeutics

Intensity Therapeutics offers a comprehensive portfolio of products and services, including INT230-6 and DfuseRx℠. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

A drug designed to kill tumors and activate immunity.

A platform enhancing drug absorption in solid tumors.

People of Intensity Therapeutics
Headcount 1-10
Employee Profiles 6
Board Members and Advisors 7
Employee Profiles
People
Brian Schwartz
EVP, Clinical Development
People
John Wesolowski
Principal Accounting Officer And Controller
People
Lewis H. Bender
Founder & CEO
People
Karen Du
Director

Unlock access to complete

Board Members and Advisors
people
Mark A. Goldberg
Director
people
Emer Leahy
Director

Unlock access to complete

Funding Insights of Intensity Therapeutics

Intensity Therapeutics has successfully raised a total of $20.98M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $6.5 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 6
  • Last Round Series B — $6.5M
  • First Round

    (26 Feb 2013)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2018 Amount Series B - Intensity Therapeutics Valuation

investors

Jun, 2016 Amount Series A - Intensity Therapeutics Valuation

investors

Apr, 2016 Amount Series A - Intensity Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Intensity Therapeutics

Intensity Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Fastforward Innovations, SalvaRx and VCapital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investment opportunities are provided for accredited investors.
Founded Year Domain Location
Venture capital investment opportunities are provided for accredited investors.
Founded Year Domain Location
Tech & life Science focused early stage VC firm investing in North America & Europe
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Intensity Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Intensity Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Intensity Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Intensity Therapeutics

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Intensity Therapeutics

Frequently Asked Questions about Intensity Therapeutics

When was Intensity Therapeutics founded?

Intensity Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.

Where is Intensity Therapeutics located?

Intensity Therapeutics is headquartered in Westport, United States.

Is Intensity Therapeutics a funded company?

Intensity Therapeutics is a funded company, having raised a total of $20.98M across 6 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Feb 26, 2013.

How many employees does Intensity Therapeutics have?

As of Dec 31, 2024, the latest employee count at Intensity Therapeutics is 16.

What does Intensity Therapeutics do?

Intensity Therapeutics is engaged in creating innovative cancer treatments through intratumoral delivery technology. The companys approach is centered on killing cancer cells while activating systemic immune responses. Solutions are developed for metastatic and presurgical patients to extend life and prevent recurrence. The healthcare sector, specifically oncology, is the primary focus of their research and clinical trials.

What products or services does Intensity Therapeutics offer?

Intensity Therapeutics offers INT230-6 and DfuseRx℠.

Is Intensity Therapeutics publicly traded?

Yes, Intensity Therapeutics is publicly traded on NASDAQ under the ticker symbol INTS.

Who are Intensity Therapeutics's investors?

Intensity Therapeutics has 4 investors. Key investors include Fastforward Innovations, SalvaRx, VCapital, and VCapital.

What is Intensity Therapeutics's ticker symbol?

The ticker symbol of Intensity Therapeutics is INTS on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available